Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline

Blood (2025) 146 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2025-1682

Published: 2025

Journal Articles

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth-Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carre, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon-Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Herve Dombret, Gunnar Juliusson, Anna Robelius, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Mariluz Amigo, Patricia Garcia Ramirez, Claudia Sossa, Juan Manuel Alonso-Dominguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Mueller-Tidow, Claudia Baldus, Jurjen Versluis, Peter Valk, Daniel Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lazarevic, Christian Recher

Blood (2025) 146 (Supplement 1): 991.

https://doi.org/10.1182/blood-2025-991

Published: 2025

Journal Articles

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

Blood (2025) 146 (Supplement 1): 37.

https://doi.org/10.1182/blood-2025-37

Published: 2025

Journal Articles

Real-world patterns of treatment intensity and prognostic model performance in older AML: Insights from the french ALFA-PPP cohort

Blood (2025) 146 (Supplement 1): 454.

https://doi.org/10.1182/blood-2025-454

Published: 2025

Journal Articles

Real life treatments and outcomes of older patients aged more than 60 years with FLT3-mutated acute myeloid leukemia: Report from the multicentric french observational ALFA-PPP study

Blood (2025) 146 (Supplement 1): 449.

https://doi.org/10.1182/blood-2025-449

Published: 2025

Journal Articles

Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.

Blood (2025) 146 (Supplement 1): 6386.

https://doi.org/10.1182/blood-2025-6386

Published: 2025

Journal Articles

Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood (2024) 144 (Supplement 1): 3483.

https://doi.org/10.1182/blood-2024-198603

Published: 2024

Journal Articles

Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup

Blood (2024) 144 (Supplement 1): 227.

https://doi.org/10.1182/blood-2024-194060

Published: 2024

Journal Articles

Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood (2024) 144 (Supplement 1): 4909.

https://doi.org/10.1182/blood-2024-203964

Published: 2024

Journal Articles

Erythroid-Specific Chimerism Analysis after Allogeneic-Hematopoietic Stem Cell Transplantation Using a Human Leukocyte Antigen-Identical Sibling Donor in Sickle Cell Disease Patients

Gonzalo De Luna, Nicolas Hebert, Ivan Sloma, Florence Beckerich, Rabah Redjoul, Anoosha Habibi, Mathieu Leclerc, Vincent Parinet, Christine Robin, Cécile Pautas, Stephane Moutereau, Fatima Bensiradj, Meghan Perkins, France Pirenne, Dehbia Menouche, Pablo Bartolucci, Sébastien Maury

Blood (2024) 144 (Supplement 1): 4875.

https://doi.org/10.1182/blood-2024-209526

Published: 2024

Journal Articles

Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study

Blood (2024) 144 (Supplement 1): 2424.

https://doi.org/10.1182/blood-2024-207226

Published: 2024

Journal Articles

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Alexis Maillard, Rabah Redjoul, Marion Klemencie, Hélène Labussière Wallet, Amandine Le Bourgeois, Maud D'Aveni, Anne Huynh, Ana Berceanu, Tony Marchand, Sylvain Chantepie, Carmen Botella Garcia, Michael Loschi, Magalie Joris, Cristina Castilla-Llorente, Anne Thiebaut-Bertrand, Sylvie François, Mathieu Leclerc, Patrice Chevallier, Stephanie Nguyen

Blood (2022) 139 (1): 134–137.

https://doi.org/10.1182/blood.2021014232

Published: 2022

Includes: Supplemental data

Journal Articles

Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients

Alexis Maillard, Rabah Redjoul, Marion Klemencie, Hélène Labussière, Amandine Le Bourgeois, Maud d'Aveni, Anna Berceanu, Sylvain Chantepie, Carmen Botella, Michael Loschi, Magalie Joris, Cristina Castilla-Llorente, Sylvie Francois, Mathieu Leclerc, Patrice Chevallier, Stephanie Nguyen Quoc

Blood (2021) 138 (Supplement 1): 336.

https://doi.org/10.1182/blood-2021-149495

Published: 2021

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?

Mathieu Leclerc, Régis Peffault de Latour, Mauricette Michallet, Didier Blaise, Patrice Chevallier, Pierre-Simon Rohrlich, Pascal Turlure, Stéphanie Nguyen, Fabrice Jardin, Ibrahim Yakoub-Agha, Sébastien Maury

Blood (2017) 129 (9): 1227–1230.

https://doi.org/10.1182/blood-2016-09-726653

Published: 2017

Includes: Supplemental data

Journal Articles

Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells

Mathieu Leclerc, Sina Naserian, Caroline Pilon, Allan Thiolat, Gaëlle H. Martin, Charlotte Pouchy, Claude Dominique, Yazid Belkacemi, Frédéric Charlotte, Sébastien Maury, Benoit L. Salomon, José L. Cohen

Blood (2016) 128 (12): 1651–1659.

https://doi.org/10.1182/blood-2016-02-700849

Published: 2016

Includes: Supplemental data

Journal Articles

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)

Mathieu Leclerc, Régis Peffault de Latour, MD, Mauricette Michallet, MD PhD, Didier Blaise, Patrice Chevallier, MD PhD, Pierre-Simon Rohrlich, MD PhD, Pascal Turlure, MD, Stéphanie Nguyen, Fabrice Jardin, Ibrahim Yakoub-Agha, Leila Moukhtari, Nicole Raus, Sébastien Maury

Blood (2015) 126 (23): 3208.

https://doi.org/10.1182/blood.V126.23.3208.3208

Published: 2015

Journal Articles

Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases

Mathieu Leclerc, MD, Felipe Suarez, MD, PhD, Marie-Pierre Noël, MD, Anne Vekhoff, MD, Xavier Troussard, MD, Jean-François Claisse, MD, Catherine Thieblemont, MD, PhD, Frédéric Maloisel, MD, PhD, Yves Beguin, MD, PhD, Jérôme Tamburini, MD, PhD, Coralie Barbe, MD, Alain Delmer, MD

Blood (2013) 122 (21): 5308.

https://doi.org/10.1182/blood.V122.21.5308.5308

Published: 2013

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

Real-world patterns of treatment intensity and prognostic model performance in older AML: Insights from the french ALFA-PPP cohort

Real life treatments and outcomes of older patients aged more than 60 years with FLT3-mutated acute myeloid leukemia: Report from the multicentric french observational ALFA-PPP study

Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.

Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup

Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Erythroid-Specific Chimerism Analysis after Allogeneic-Hematopoietic Stem Cell Transplantation Using a Human Leukocyte Antigen-Identical Sibling Donor in Sickle Cell Disease Patients

Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?

Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)

Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only